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Abstract
Introduction: Chronic low-grade inflammation is a significant factor in the development of obesity associated diabetes.
This is supported by recent studies suggesting endotoxin, derived from gut flora, may be key to the development of
inflammation by stimulating the secretion of an adverse cytokine profile from adipose tissue.
Aims: The study investigated the relationship between endotoxin and various metabolic parameters of diabetic patients
to determine if anti-diabetic therapies exerted a significant effect on endotoxin levels and adipocytokine profiles.
Methods: Fasting blood samples were collected from consenting Saudi Arabian patients (BMI: 30.2 ± (SD)5.6 kg/m2, n
= 413), consisting of non-diabetics (ND: n = 67) and T2DM subjects (n = 346). The diabetics were divided into 5
subgroups based on their 1 year treatment regimes: diet-controlled (n = 36), metformin (n = 141), rosiglitazone (RSG:
n = 22), a combined fixed dose of metformin/rosiglitazone (met/RSG n = 100) and insulin (n = 47). Lipid profiles, fasting
plasma glucose, insulin, adiponectin, resistin, TNF-α, leptin, C-reactive protein (CRP) and endotoxin concentrations
were determined.
Results: Regression analyses revealed significant correlations between endotoxin levels and triglycerides (R2 = 0.42; p <
0.0001); total cholesterol (R2 = 0.10; p < 0.001), glucose (R2 = 0.076; p < 0.001) and insulin (R2 = 0.032; p < 0.001) in
T2DM subjects. Endotoxin showed a strong inverse correlation with HDL-cholesterol (R2 = 0.055; p < 0.001). Further,
endotoxin levels were elevated in all of the treated diabetic subgroups compared with ND, with the RSG treated
diabetics showing significantly lower endotoxin levels than all of the other treatment groups (ND: 4.2 ± 1.7 EU/ml, RSG:
5.6 ± 2.2 EU/ml). Both the met/RSG and RSG treated groups had significantly higher adiponectin levels than all the other
groups, with the RSG group expressing the highest levels overall.
Conclusion: We conclude that sub-clinical inflammation in T2DM may, in part, be mediated by circulating endotoxin.
Furthermore, that whilst the endotoxin and adipocytokine profiles of diabetic patients treated with different therapies
were comparable, the RSG group demonstrated significant differences in both adiponectin and endotoxin levels. We
confirm an association between endotoxin and serum insulin and triglycerides and an inverse relationship with HDL.
Lower endotoxin and higher adiponectin in the groups treated with RSG may be related and indicate another mechanism
for the effect of RSG on insulin sensitivity.
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Introduction
In recent years, obesity, insulin resistance, as well as many
of the features that comprise the metabolic syndrome, are
associated with a low-grade, systemic, inflammatory con-
dition [1,2]. In particular, the mediation of this sub-clini-
cal inflammation in the pathogenesis of Type 2 Diabetes
Mellitus (T2DM) is proposed to arise through increasing
adiposity [3,4]; with adipose tissue representing a site of
an acute phase response [5,6] through the production of
known pro-inflammatory adipocytokines such as leptin,
tumor necrosis factor (TNF-α) and interleukin (IL-6),
amongst others [7-9]. Specifically, adipocytokines appear
to have a duality of function, simultaneously mediating
inflammation and insulin resistance through their effects
on insulin action. Therefore, adipocytokines may func-
tion as a consequence of the cross-link proposed between
metabolic and inflammatory pathways in adipocytes and
immune cells [10-12].
Current therapies utilized in the treatment of T2DM
include metformin and the thiazolidinediones (TZDs).
These agents have principally been evaluated on the basis
of their beneficial effects on glucose metabolism, due to
their insulin enhancing properties. Metformin and rosigl-
itazone (RSG) are widely accepted first-line anti-diabetic
drug therapies, whether taken as a monotherapy or in
combination [13], and are considered effective with low
incidence of hypoglycemia [14]. In addition to their
effects on glucose homeostasis, metformin, itself, is
known to reduce leptin, with resultant effects on inflam-
matory status and satiety [15]. Furthermore, the TZDs
have previously been shown to have immunomodulatory
effects [16]; reducing inflammation in both in-vitro and
in-vivo models [17-19]. These findings highlight alterna-
tive pathways through which drug therapies are able to
counteract the progressive nature of metabolic disease and
their potential dual action on reducing obesity mediated
T2DM.
Whilst metformin and the TZDs appear to offer dual func-
tionality in insulin resistance and inflammation, the ini-
tial mediator for such an inflammatory insult is less well
understood. One source of sub-clinical inflammation in
patients with T2DM and coronary heart disease may arise
through commensal bacteria derived from the gut,
referred to as endotoxin [20]. Endotoxin is derived from
lipopolysaccharide (LPS), which represents cell wall frag-
ments of gram negative bacteria. Previous studies have
demonstrated that subjects with obesity and T2DM have
elevated circulating levels of endotoxin compared with
non-diabetics (ND), which has been implicated in
increased inflammatory risk [21]. Further support for this
concept has arisen in subsequent studies where serum
endotoxin levels are significantly higher in ob/ob and db/db
mice compared with their normal weight counterparts
[22]. Studies suggest elevated endotoxin levels may arise
as a result of obesity related hyperinsulinemia; hence low-
grade endotoxinemia may be caused by the effect of insu-
lin on intestinal motility and/or intestinal permeability.
In support of this theory, murine studies analyzing the
gastrointestinal tract (GIT) of ob/ob and db/db mice identi-
fied pathological changes in the GIT cells. The findings
indicated that insulin may act directly on the GIT to affect
gut permeability and potentially increase endotoxin
absorption [22]. Elevated circulating levels of endotoxin
may then initiate an inflammatory response within adi-
pose tissue, via innate immunity, in conjunction with the
liver, as the latter is the primary site of endotoxin clear-
ance under normal physiological circumstances [6,22].
This mechanism may, therefore, explain the state of sub-
clinical inflammation often present in obese and type 2
diabetic subjects [2].
Whilst limited data have been presented on the increase of
endotoxin in pathological conditions such as obesity and
diabetes, no data, as yet, have evaluated the influence of
insulin sensitizers, in combination, on inflammatory risk
posed by circulating endotoxin. Whilst there is a large
quantity of data available on obesity and T2DM in rela-
tion to the Western world, less information exists regard-
ing populations in the transitional state. In particular,
Saudi Arabia has experienced a rapid increase in wealth
over a relatively short period of time as a consequence of
the financial gains rendered by the oil industry, paralleled
with swift industrialization and urbanization [23]. As a
result, the burden of disease in Saudi Arabia is high. The
Obesity Taskforce worldwide projections for 2030 predict
that the incidence of diabetes will rise by 32% in Europe,
72% in the USA but will increase by a massive 164% in
the Middle East [24,25]. As such, it is clear we need to
have a fundamental understanding of their risk of inflam-
mation and how insulin sensitizers, along with other ther-
apies, may reduce such a risk.
Therefore, the aims of this present study were to establish
any associations between endotoxin and insulin, glucose,
lipid profiles and pro-inflammatory cytokines in a Saudi
Arabian cohort consisting of obese, ND subjects and
obese, T2DM patients on various anti-diabetic therapies.
Furthermore, the study aimed to examine the influence of
diet, metformin, RSG, met/RSG as well as insulin on
endotoxin levels and its' association with inflammation.
Ultimately, this study will evaluate whether alterations in
endotoxin, coupled with altered metabolic profile, in type
2 diabetics might further explain the observed improve-
ment in the clinical profiles of patients treated with these
therapies. This present study, in combination with our
previous findings, may therefore help determine endo-
toxin as a novel biomarker of T2DM and diabetic risk and
hence proffer a new target for the treatment or prevention
of diabetes.Cardiovascular Diabetology 2009, 8:20 http://www.cardiab.com/content/8/1/20
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Methodology
This single-centre, prospective and cross-sectional study
was carried out at the Diabetes Center of King Abdul-aziz
University Hospital in Riyadh, Kingdom of Saudi Arabia.
The study protocol was approved by the institutional
review board and was conducted in accordance with the
guidelines set by the College of Medicine and Research
Center of King Saud University, Riyadh, Kingdom of
Saudi Arabia ethics committee. All patients submitted
written and informed consent prior to inclusion.
Subjects
The study consisted of a total of 413 out-patients (male:
203; female: 210) age 20–80. Furthermore, 346 subjects
were known type 2 diabetics, while the remaining 67 were
ND, closely matched for BMI.
Inclusion criteria for the diabetics (prior diagnosis) were
determined in the first screening visit and included HBA1c
6–11%, fasting plasma glucose 7.0–14.0 mmol/l; BMI
22–40 kg/m2; without co-existing diabetic complications,
i.e. diabetic retinopathy, nephropathy, etc. Subjects must
have received treatment (diet controlled, metformin, RSG,
met/RSG or insulin) for at least one year. ND subjects had
normal fasting plasma glucose (<5.6 mmol/l); HBA1c lev-
els (4–6%) and were not taking any medications prior to
commencement of research. Patients were excluded if
they had poorly controlled diabetes with co-existing com-
plications, smoking history, history of coronary heart dis-
ease and any unstable medical condition/s that would
require immediate attention.
All subjects underwent a complete physical examination,
which included an electrocardiogram prior to enrolment.
Qualified patients were then stratified into 6 groups on
the basis of their hypoglycemic therapies (diet-controlled
(n = 36), metformin (n = 141), RSG (n = 22), met/RSG (n
= 100) and insulin (n = 47)), in addition to the ND group
(n = 67). Following the findings of the initial study, a sub-
group of diabetic subjects (n = 11, BMI 31.7 ± 6.42 kg/m2)
were treated with RSG for a period of 6 months (Post RSG:
BMI 30.9 ± 4.42 kg/m2), in order to determine the specific
effect of RSG treatment on endotoxin levels.
In vivo Assessment of the Biochemical profile, 
Adipocytokines and Endotoxin Levels
On the assigned date, fasting blood samples were col-
lected from participating subjects and lipid profiles and
fasting plasma glucose determined using routine labora-
tory methods. Adipocytokine levels were also assessed
using various sandwich enzyme-linked immunosorbent
assays (ELISAs). These included adiponectin (Linco Ltd,
USA; intra-assay variability 7.0%, interassay variability
8.4%), resistin (RnD Systems Ltd, UK; intra- 4.0%, inte-
rassay variability 7.7%), TNF-α (RnD Systems Ltd, UK;
intra- 5.2%, interassay variability 7.4%), leptin (intra-
3.3%, interassay variability 5.4%) and C-reactive protein
(CRP, Immunodiagnoztik AG, Germany; intra- 6%, inte-
rassay variability 11.6%). Insulin was analyzed via a solid
phase enzyme amplified sensitivity immunoassay
(Medgenix INS-ELISA, Biosource, Belgium). Lastly, endo-
toxin concentration was measured using a chromogenic
kinetic limulus amebocyte assay (LAL assay, BioWhitaker,
Walkersville MD), which had been validated, previously
[21].
Statistical Analyses
Data were analyzed using the Statistical Package SPSS for
Windows, version 11.5. Data were expressed as mean ±
standard deviation and mean (interquartile range) if not
normally distributed. Groups were compared using
ANOVA with Bonferroni adjustments for inter group
comparisons. Simple and partial correlation coefficients
between the variables were determined and multiple
regression analysis was carried out to determine variables
of interest. Triglycerides, insulin, leptin, adiponectin,
CRP, resistin and endotoxin were logarithmically trans-
formed to normalize data before correlations and statisti-
cal analyses were performed.
Results
Metabolic and Clinical Characteristics
Baseline characteristics
Table 1 shows the clinical and metabolic characteristics of
the 6 groups analyzed in this study. The mean systolic
blood pressures of the groups were similar, with the diet
and RSG treated group having the lowest mean systolic
blood pressures (111.6 ± 22.9 mmHg and 114.1 ± 28.7
mmHg, respectively) and the met/RSG group (128.4 ±
23.6 mmHg, p < 0.05) the highest. The mean diastolic
blood pressures of the ND (84.1 ± 14.6 mmHg) and met/
RSG treated groups (84.6 ± 13.0 mmHg) were signifi-
cantly lower than the insulin treated group (96.0 ± 15.5
mmHg, p < 0.05). Waist to hip ratios (WHR) were similar
across all groups with the insulin treated group showing
the highest WHR (1.4 ± 0.4), that differed significantly
from the ND and the met/RSG treated groups (ND: 1.1 ±
0.2; met/RSG: 1.1 ± 0.3, p < 0.05). As would be expected,
the ND group had significantly lower fasting plasma glu-
cose levels compared with the other 5 groups. The groups
were comparable in terms of lipid profile, although only
the triglyceride levels in the diet and RSG treated groups
(diet: 1.6(0.9–2.3) mmol/l; RSG: 1.6(0.8–2.3) mmol/l, p
< 0.05) did not differ significantly from the ND group
(1.4(1.0–1.9) mmol/l, table 1).
Associations Between Endotoxin levels and Metabolic Factors in 
Subjects with T2DM
Regression analyses revealed a significant correlation
between endotoxin levels and triglycerides (R2 = 0.42; p <Cardiovascular Diabetology 2009, 8:20 http://www.cardiab.com/content/8/1/20
Page 4 of 10
(page number not for citation purposes)
0.0001, figure 1a); an inverse correlation between HDL-
cholesterol values (R2 = 0.055; p < 0.001, figure 1b) and a
significant correlation between total cholesterol levels (R2
= 0.10; p < 0.001, figure 1c) in the diabetic cohort. The
correlation between endotoxin levels and triglycerides, as
well as cholesterol, remained even in the absence of dia-
betes (R2 = 0.192; p < 0.0001, figure 2a; R2 = 0.163; p <
0.001, figure 2c). Lastly we found a significant association
between endotoxin levels and insulin (R2 = 0.032; p <
0.001, figure 3a) and glucose (R2 = 0.076; p < 0.001, figure
3b) in the type 2 diabetics, which was not present in the
ND group (figure 3c and 3d). The rest of the analyses were
not significant.
Circulating Endotoxin Levels in ND and Treated T2DM Subjects
Serum endotoxin levels were lowest in the ND group
(4.2(3.1–5.1) EU/ml, table 1), with the insulin treated
cohort exhibiting the highest levels (9.2(6.6–10.7) EU/
ml, table 1). Only the RSG treated group showed signifi-
cantly lower endotoxin levels than all of the other anti-
diabetic therapies (RSG: 5.65(4.2–6.1) EU/ml, table 1).
Compared with baseline values, endotoxin levels showed
Table 1: Clinical and Metabolic Characteristics of Subjects
Variables Non-Diabetic Diet Insulin Metformin Rosiglitazone Met/RSG
Age (years) 44.1 ± 9.9§‡*†** 48.3 ± 9.1‡*** 55.6 ± 11.4 53.0 ± 10.5 52.3 ± 9.5 52.5 ± 9.0
BMI (kg/m2) 30.0 ± 5.2 29.6 ± 5.8 29.0 ± 6.2 32.0 ± 5.8 29.6 ± 5.8 31.0 ± 5.3
Systolic (mmHg) 117.3 ± 20.0 111.6 ± 22.9*** 115.7 ± 24.9** 123.8 ± 23.5 114.1 ± 28.7** 128.4 ± 23.6
Diastolic (mmHg) 84.1 ± 14.6‡* 88.2 ± 14.9‡ 96.0 ± 15.5*** 90.3 ± 14.3** 90.9 ± 16.3 84.6 ± 13.0
WHR 1.1 ± 0.2§‡† 1.3 ± 0.4** 1.4 ± 0.4** 1.3 ± 0.4** 1.3 ± 0.3** 1.1 ± 0.3
Glucose (mmol/l) 5.5 ± 1.5§‡*†** 7.1 ± 2.8‡*** 9.5 ± 3.8 9.6 ± 3.4 8.4 ± 1.9 9.4 ± 3.9
Insulin (ng/ml)# 20.1(10.9–23.0)‡ 19.1(10.7–24.6)‡ 29.9(21.2–36.6)*** 20.7(10.9–27.3) 21.5(11.8–20.5) 17.1(7.6–17.2)
LDL-C (mmol/l) 3.2 ± 0.9§* 2.7 ± 0.8 3.0 ± 1.0 2.8 ± 0.8 2.8 ± 0.7 3.0 ± 1.4
HDL-C (mmol/l) 1.2 ± 0.4 1.3 ± 0.7 1.1 ± 0.4 1.1 ± 0.4 1.0 ± 0.4 1.2 ± 0.5
TC (mmol/l) 5.0 ± 1.0 4.7 ± 1.0 4.9 ± 1.1 4.8 ± 1.0 4.5 ± 0.9** 5.1 ± 1.2
TG (mmol/l)# 1.4 (1.0–1.9)*** 1.6(0.9–2.3)*** 1.8(1.2–2.4) 2.1(1.3–2.4) 1.6(0.8–2.3) 2.2(1.3–2.5)
Leptin (ng/ml)# 31.0(14.6–42.2)§*†** 18.2(5.8–23.4)‡ 27.5(9.8–39.3)†** 22.5(9.6–29.6)** 16.2(5.2–19.8) 18.6(4.9–21.7)
Adiponectin (μg/ml)# 8.5(5.1–1.0) †** 8.6 (5.7–10.4)†** 10.4 (5.3–13.2)†** 9.1(6.0–11.3)†** 16.1(10.2–20.1) 14.3(8.9–16.1)
CRP(μg/ml)# 4.2(1.1–5.2) 3.8 (2.5–4.9)‡ 6.3 (1.5–6.5)** 4.6(1.3–4.7) 3.7(0.8–4.6) 3.6(1.0–3.9)
Resistin (ng/ml)# 15.6(10.7–19.8)† 15.0(14.5–17.9)† 17.6(10.5–18.4)†** 16.1(11.3–18.1)†** 11.9(8.0–13.7)** 14.2(10.4–16.7)
TNF-α (pg/ml)# 5.4(3.4–7.3)*** 4.7(2.9–6.2) 5.4 (2.7–7.4)* 4.2(2.8–5.3)† 5.9(4.3–6.8)** 4.5(3.3–5.6)
Endotoxin(EU/ml)# 4.2(3.1–5.1)§‡*†** 7.9(5.7–10.0)† 9.2 (6.6–10.7)*†** 7.5(4.6–8.7)† 5.6 (4.2–6.1)** 7.4 (4.8–9.6)
Clinical characteristics for non-diabetic (ND) and T2DM subjects on anti-diabetic therapies. Variables marked with # were log transformed prior to 
statistical analysis. Hence data are presented as mean ± SD unless log transformed (#) in which case they are presented as mean (interquartile 
range). Significance was set at p < 0.05. Therefore §denotes a significant difference in the mean values when compared with diet; ‡ denotes 
significance when compared with insulin; *denotes significance when compared with metformin; † denotes significance compared with RSG; ** 
denotes significance when compared with met/RSG.Cardiovascular Diabetology 2009, 8:20 http://www.cardiab.com/content/8/1/20
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Correlations between log fasting endotoxin (EU/ml) and a)  log triglycerides (mmol/l), b) HDL (mmol/l) and c) choles- terol (mmol/l) in the whole diabetic cohort Figure 1
Correlations between log fasting endotoxin (EU/ml) 
and a) log triglycerides (mmol/l), b) HDL (mmol/l) 
and c) cholesterol (mmol/l) in the whole diabetic 
cohort. The lines of best fit are also shown: a) R2 = 0.42, p < 
0.0001, b) R2 = 0.055, p < 0.001, c) R2 = 0.1, p < 0.001).
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a 13.5% decrease post treatment with RSG (Figure 4, p <
0.05).
Circulating Adipocytokine Levels
With regard to adipocytokines, the leptin levels of the ND
group (31.0(14.6–42.2) ng/ml) were significantly higher
compared with the treated type 2 diabetic subgroups
(table 1). Adiponectin levels in the RSG (16.1(10.2–20.1)
μg/ml) and met/RSG (14.3(8.9–16.1) μg/ml) treated
groups were significantly higher than all the other groups,
with the RSG group showing almost a two fold increase in
adiponectin levels compared with the ND (8.5(5.1–10.0)
μg/ml, table 1). The mean resistin levels of the groups
were comparable, except for the RSG group which showed
the lowest resistin levels overall (11.9(8.0–13.7)ng/ml, p
< 0.05, table 1). CRP levels were highest in the insulin
Correlations between log endotoxin (EU/ml) and a) log fasting insulin (ng/ml) and b) glucose (mmol/l) in the whole diabetic  cohort Figure 3
Correlations between log endotoxin (EU/ml) and a) log fasting insulin (ng/ml) and b) glucose (mmol/l) in the 
whole diabetic cohort. The lines of best fit are also shown: a) R2 = 0.032, p < 0.001, b) R2 = 0.076, p < 0.001. Correlations 
between log endotoxin (EU/ml) and c) log fasting insulin (ng/ml) and d) glucose (mmol/l) in the non-diabetic (ND) group. The 
lines of best fit are also shown: c) R2 = 0.025, NS; d) R2 = 0.009, NS.
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treated diabetics (6.3(1.5–6.5) μg/ml, p < 0.05, table 1),
whilst TNF-α levels were significantly higher in the RSG
treated group (5.9(4.3–6.8) pg/ml, p < 0.05, table 1).
Discussion
Recent studies have implicated a role for adipose tissue as
a site of systemic inflammation, thus providing a direct
link between obesity and the associated state of chronic
sub-clinical inflammation [2]. One principal source for
inflammatory risk may occur via the gastrointestinal tract
(GIT), as previous studies have determined that endo-
toxin can activate the innate immune response within adi-
pose tissue [16,21,22,26,27]. Such studies signify a
potential role for gut flora related induction of innate
immunity and circulating endotoxin in the pathogenesis
of obesity induced T2DM.
The findings from this study have highlighted that sub-
jects with T2DM had significantly elevated levels of endo-
toxin compared with BMI matched ND subjects. Hence,
these studies have affirmed previous findings in Cauca-
sian populations whilst increasing the studied subjects'
numbers four fold [21]. Our findings also demonstrated
that insulin treated subjects exhibited the highest circulat-
ing endotoxin levels of all the cohorts examined; addi-
tionally, both insulin and glucose were shown to correlate
significantly with endotoxin levels in the diabetic cohort
but not in the control group. As such, our current and pre-
vious data have highlighted an association between insu-
lin and endotoxin, suggesting a mechanism that
hyperinsulinemia/insulin resistance may lead to
increased absorption of endotoxin through the GIT
[22,28]. Whilst the findings of the present study support
the endotoxin/gut absorption hypothesis, it has not deter-
mined a causal effect and further studies would be
required to examine this theory. Therefore, endotoxin
may act as an inflammatory mediator in T2DM [21,22].
However our understanding of the relationship between
glucose and endotoxin is less clear, as previous studies
show no correlation between glucose levels and endo-
toxin [21], with Pederson and colleagues observing only a
moderate increase in glucose levels when subjects under-
went endotoxin infusion [29]. Conversely, severe human
sepsis is known to instigate a hypermetabolic stress
response, which includes hyperglycemia and impaired
glucose tolerance [30]. Studies in T2DM patients have
demonstrated that elevated glucose levels interfere with
macrophage function, suppressing the bactericidal capac-
ity of leukocytes [30], whilst murine studies have shown
elevated glucose levels cause adverse effects on jejunum
motility [31]. As such, hyperglycemia may make patients
more susceptible to further infection – as observed in
T2DM – as well as potentiating endotoxin absorption
through inhibition of gut motility. Although patients with
septic shock have considerably higher endotoxin levels
(10 – 50 fold) than type 2 diabetics [32], subjects with cir-
rhosis are comparable with obese and T2DM subjects
[33]. Therefore an association between glucose and endo-
toxin would suggest a role for endotoxin as an inflamma-
tory mediator [34]. Our current findings have identified a
clear, positive correlation between endotoxin and glucose
serum levels [21]. The apparent discrepancies between our
study and previous findings may have arisen due to the
large size of the cohort we examined. Therefore the rela-
tionship between endotoxin and glucose should be inves-
tigated through subsequent studies to corroborate our
findings.
The strong positive correlation identified between endo-
toxin and triglyceride levels is also of interest, noted in
both the T2DM subjects and ND group. It is well estab-
lished that subjects with obesity and T2DM have high
serum triglyceride and low HDL [35,36]. Studies have
indicated that HDL has a protective role against inflam-
mation and the effects of endotoxin [37,38]. Low levels of
HDL are associated with low levels of sCD14 [39], which
corresponds with data showing that LPS binds to HDL in
the presence of sCD14 and LPS binding protein (LBP)
[40-42], and enzymes involved in the presentation of LPS
to sCD14. This would imply that HDL is potentially
involved in the immunological response to LPS. In con-
trast, serum triglyceride levels are directly stimulated by
LPS [43] and are correlated with sCD14 [44]. Further-
more, it may act as a carrier of bacterial antigens and also
facilitate their clearance [45,46]. These findings would
have obvious implications in obese, T2DM patients.
Upon comparison of the different treatment regimes, only
the RSG group showed circulating endotoxin levels signif-
The mean levels of endotoxin (EU/ml) in sera from T2DM  patients, pre and post RSG treatment (n = 11, p < 0.05*) Figure 4
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icantly lower than all of the other anti-diabetic therapies.
The insulin treated cohort showed the highest circulating
levels of endotoxin, which advocates the theory that insu-
lin may promote increased endotoxin absorption from
the GIT [22]. Furthermore, all of the cohorts on anti-dia-
betic drug treatments, metformin, RSG and met/RSG,
showed significantly lower levels of endotoxin than insu-
lin – with the RSG treated group exhibiting the most dra-
matic decrease. Upon further analysis of pre and post RSG
treated T2DM subjects, there was a 13.5% decrease in
endotoxin levels over a 6 month period. These results con-
firm previous studies to show that RSG significantly
reduces endotoxin in T2DM patients [21], whilst also
indicating that RSG has a more significant effect on endo-
toxin levels than other anti-diabetic therapies. Therefore,
these findings may explain some of the anti-inflammatory
properties of the TZDs.
In addition, RSG and met/RSG treated subjects both
resulted in elevated adiponectin levels that, whilst compa-
rable to one another, were significantly higher than all the
other treated groups, including the ND group. These data
affirm findings by Rosenstock and colleagues and support
their suggestion that the observed increase in adiponectin
is due to RSG, as the TZDs have been shown to consist-
ently increase circulating adiponectin [47].
Assessment of other adipocytokines showed that leptin
levels were highest amongst the ND group and did not
correlate with endotoxin in all groups. However, to date,
the findings regarding leptin are conflicting. Patients with
sepsis are known to have elevated levels of leptin [48], yet
several studies have failed to demonstrate an increase in
leptin with endotoxin infusion [49,50], whilst studies in
mice and hamsters show increased leptin at the serum and
mRNA level with endotoxin administration [51,52]. Such
differences may have arisen from methodological reasons,
as our study measured the relationship between leptin
and endogenous endotoxin serum levels, as opposed to
the effects on leptin as a result of exogenous endotoxin
administration. Furthermore, within this study, the dia-
betic drugs may have decreased leptin concentration,
altering the determined findings [15,53].
In summary, both ND and diabetic subjects showed sig-
nificant associations with endotoxin and triglycerides and
total cholesterol. T2DM subjects demonstrated an inverse
correlation between endotoxin and HDL-cholesterol and
positive correlations between endotoxin and glucose and
endotoxin and insulin. As such, endotoxin may mediate
various metabolic changes in people with T2DM in
response to an increasing insulin resistant state, which is
also consistent with chronic systemic low-grade inflam-
mation. Our data suggest that the sub-clinical inflamma-
tion observed in T2DM patients may, in part, be derived
from commensal bacteria [54]. Whilst clinical treatment
of T2DM implies that RSG has the most favorable effect
on overall endotoxin reduction and adipocytokine pro-
files in the T2DM patients, the present studies have simply
identified associations and clearly additional randomized
studies are required to determine the cause and effect via
further examination of the role of endotoxin and the insu-
lin resistant state. However current data suggest that endo-
toxin may represent an important mediator for
inflammatory related metabolic risk.
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